Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis
Authors:
- 14 August 2022
- journal article
- review article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 40 (9) , 777-788
Abstract
A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI) compared to NIVO monotherapy among cancer patients. We searched several databases to identify relevant RCTs. Meta-analysis was performed using random-effects model. In fourteen RCTs included in the study, we found that compared to NIVO monotherapy, combination NIVO + IPI increased the risk of any grade (Risk Ratio (RR)=1.11), and grade 3 or 4 (RR =1.95) TRAEs. Compared to NIVO, NIVO + IPI had higher risk for any grade colitis (RR =4.52), pneumonitis (RR =3.06), and diarrhea (RR =1.68).Keywords
This publication has 29 references indexed in Scilit:
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trialsThe Lancet Oncology, 2018
- Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic reviewCancer Letters, 2018
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143Neuro-Oncology, 2017
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 TherapyJournal of Clinical Oncology, 2017
- Gastrointestinal and Hepatic Complications of Immune Checkpoint InhibitorsCurrent Gastroenterology Reports, 2017
- Predictive biomarkers for checkpoint inhibitor-based immunotherapyThe Lancet Oncology, 2016
- Factors Associated with Health-Related Quality of Life Among Colorectal Cancer SurvivorsAmerican Journal of Preventive Medicine, 2015
- Product Review: Covidence (Systematic Review Software)Journal of the Canadian Health Libraries Association / Journal de l'Association des bibliothèques de la santé du Canada, 2014
- Combining immunotherapy and targeted therapies in cancer treatmentNature Reviews Cancer, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011